
Morten Søgaard is packing up shop in New York, where he has spent the past 12 years at pharmaceutical giant Pfizer. He’s now replacing the East Coast with the West Coast, as he joins the San Francisco-based development department of Japanese Astellas Gene Therapies.
He will lead a team of around 100 people, most of whom are also situated on the Western Seaboard of the US, with some members in Tokyo, Japan, where Astellas is headquartered.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app